A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer

Anti-Cancer Drugs

Volumn 10, Issue 4, 1999, Pages 375-383

  Verschraegen, Claire F ^a,d   Gupta, Elora ^a   Loyer, Evelyne ^b   Kavanagh, John J ^c   Kudelka, Andrzej P ^a   Freedman, Ralph S ^b   Edwards, Creighton L ^c   Harris, Nick ^a   Steger, Melissa ^b   Steltz, Veronica ^c   Giovanella, Beppino C ^a   Stehlin, John S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c St Joseph's Medical Center Houston   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Anemia; Cystitis; Myelosuppression; Nausea; Neutropenia; Thrombocytopenia; Weight loss

Indexed keywords

9-NITROCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; RUBITECAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; UTERINE TUBE TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE;

EID: 0033110137     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199904000-00005     Document Type: Article

References (48)

1. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-93.
2. Gwyther S, Bolis G, Gore M, et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 1997; 8: 463-8.
3. Creemers GJ, Bolis G, Gore M, et al Topotecan, an active drug in the secondline treatment of epithelial ovarian cancer results of a large European phase II study. / Clin Oncol 1996; 14: 3056-61.
4. Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J, Mcguire W. A phase n trial of topotecan as salvage therapy in epithelial ovarian cancer. ProcAin Soc Clin Oncol 1995; 14: A769.
5. Gordon A, Bookman M, Malmstrom H, et al Efficacy of topotecan in advanced epithelial ovarian cancer after . failure of platinum and paclitaxel: International Topote-\v can Study Group Trial. ProcAm Soc Clin Oncol 1996; 15: A763.
6. Kudelka AP, Tresukosol D, Edwards CL, et al Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-7.
7. Takeuchi S, Dobashi K, Fujimoto S, et al A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gynecologic cancers. Jpn J Cancer Chemother 1991; 18: 1681-9-
8. Mori H, Itoh N, Kondoh H, et al Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative. EnrJ Cancer 1992; 28: 613-7.
9. Yang L, Liu LF, Li JJ, et al. The roles of DNA topoisomerase in SV 40 DNA replication. UCLA Symp Mol Cell Biol 1986; 47: 315-26.
10. Liu LF, Wang JC. Supercoiling of DNA template during transcription. Proc Natl Acad Sei USA 1987; 84: 7024-7.
11. Wang JC, Giaver GN. Action at a distance along a DNA. Science 1988; 240: 300-4.
12. Jaxel C, Kohn KW, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989; 49: 1465-9.
13. Hertzberg RP, Caranfa MJ, Holdern KG, et al. Modification of the hydroxy lactone ring of camptothecin: inliibition of mammalian topoisomerase I and biological activity. JMed Chetn 1982; 32: 15-9.
14. Wall ME, Wani MC, Cooke, et al Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inliibitor from Camptotbeca aatminata.J Am Chem Soc 1966; 88: 3888-90.
15. Burke TG, Mi Z. Preferential binding of carboxylate form of camptothecin by human serum albumin. Ann Biochem 1993; 212: 285-7.
16. Mi Z, Burke TG. Marked interspecies variations concerning interactions of camptothecin with serum albumin. Biochemistry 1994; 33: 12540-5.
17. Mi Z, Burke TG. Marked interspecies variations concerning interactions of camptothecin analogues with serum albumin. Proc Am Ass Cancer Res 1995; 36: 444.
18. Takimoto CH, Grem JL, Allegra CJ, Arbuck SG. Current status of the clinical development of 9-aminocamptothecin (9-AQ. Ann Oncol 1996; 7(suppl 1): 26.
19. Giovanella BC, Stehlin JS, Wall ME, et al DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
20. Giovanella BC, Hinz HR, Kozielski AJ, et al Complete growth inliibition of human cancer xenografts in nude mice by treatment with 20(5camptothecin. Cancer Res 1991; 51: 3052-5.
21. Verschraegen CF, Natelson EA, Giovanella BC, et al A phase I clinical and pharmacological study of oral 9nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-Cancer Dnigs 1998; 9: 36-44.
22. WHO handbook for reporting results of cancer treatment. Geneva: WHO, 1979: 48.
23. Gibaldi M. Compartmental and noncompartmental phannacokinetics. In: Biopharmacentics and clinical pbarmacokinetics. Lea & Febiger. Philadelpliia 1991: 14-23.
24. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987; 71: 1079-85.
25. Peto J. The calculation and interpretation of survival curves. In: Buyse M, Staquet M, Sylvester R, eds. Cancer clinical trials: methods and practice. Oxford: Oxford University Press 1984: 361-80.
26. Creemers GJ, Gerrits CJ, Eckardt JR, et al. Phase I and pharmacologie study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. JClin Oncol 1997; 15: 1087-93.
27. Drengler R, Burns H, Dietz A, et al. A phase I trial to evaluate orally administered irinotecan HCL (CPT11) given daily x5 ever)' 3 weeks in patients with refractor)' malignancies. Proc Am Soc Clin Oncol 1996; 15: A1560.
28. De Jonge M, Punt C, Sparreboom A, et al. Phase I and pharmacology study on oral [Peg 1000] 9-amino-carnptothecin (9-AQ in patients with advanced solid tumors. In: Proc 10th NCI-EORTC Symp on New Dntgs in Cancer Therapy, Amsterdam 1998: 64.
29. Grochow LB, Rowinsky FJC, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Dnig Metab Disp 1992; 20: 70612.
30. Rowinsky EK, Grochow LB, Hendricks CD, et al. Phase I and pharmacologie study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56.
31. Creemers GJ, BeijnenJH, Planting AS, etal. Phase I trial of low-dose continuous topotecan infusion in patients with cancer, an active and well-tolerated regimen. JClin Oncol 1994; 12: 553-9.
32. Höchster H, Speyer J, Wadler S, et al. Phase n study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer a highly active regimen. Proc Am Soc Clin Oncol 1996; 15: A775.
33. Gay C, Lokiec F, Canal P, et al. Pharmacokinetics and pharmacodynamics of the camptothecin analog CPT11 during phase II studies. Proc Am Ass Cancer Res 1994; 35: A1452.
34. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-5.
35. Rothenberg ML The current status of irinotecan (CPT-11) in the United States. Ann NYAcadSci 1996; 803: 272-81.
36. Pantazis P, Kozielski AJ, Mendoza JT, et al. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinghuish between nontumorigenic and tumorigenic cells in vitro. IntJ Cancer 1993; 53: 863-71.
37. Pantazis P, Kozielski AJ, Vardeman DM, et al. Efficacy of camptothecin congeners in the treatment of human breast carcinoma Oncol Res 1993; 5: 273-1.
38. Pantazis P, Kozielski AJ, Rodriguez R, et al. Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 1994; 4: 5-10.
39. Hinz HR, Harris NJ, Natelson EA, Giovanella DC. Pharmacokinetics of the in vitro and in vivo conversion of 9-nitro205camptothecin to 9 amino-20(5camptothecin in humans, dogs, and mice. Cancer Res 1994; 54: 3096-100.
40. Pantazis P, Harris N, Mendoza J, Giovanella B. The role of pH and serum albumin in the metabolic conversion of 9nitrocamptothecin to aminocamptothecin by human hematopoietic cells. EnrJ Hematol 1995; 55: 211-3.
41. Pantazis P, Harris N, Mendoza J, Giovanella B. Conversion of 9-nitrocamptothecin to amino-camptothecin by human blood cells in vitro. EurJ Hematol 1994; 53: 246-8.
42. Sparreboom A, Jonge MJA, Punt CJA, et al. Pharmacokinetics and bioavailability of oral 9 aminocamptothecin capsules in patients with solid tumors. Clin Cancer Res 1998; 4: 1915-9.
43. Langevin AM, Casto DT, Thomas PJ, et al. Phase I trial of 9 aminocamptothecin in children with refractor)' solid tumors: a Pédiatrie Oncology Group Study. J Clin Oncol 1998; 16: 2494-9.
44. Rubin E, Wood V, Bharti A, et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-arninocamptothecin. Clin Cancer Res 1995; 1: 269-76.
45. Dahut W, Harold N, Takimoto C, et al. Phase I and pharmacology study of 9-aminocamptothecin given by 72hour infusion to adult cancer patients./ Clin Oncol 1996; 14: 1236-44.
46. Takimoto CH, Arbuck SG. The camptothecins. In: Chabner SA, Longo DL, eds. Cancer chemotherapy anil blotherapy. Pliiladelphia: Lippincott-Raven 1996: 463-8.
47. Hoff PM, Lassere Y, Royce M, et al. Phase I study of the new camptothecin analogue DX-8951F administered by 24 hour continuous infusion. In: Proc 10th NCI-EORTC symp on New Dnigs in Cancer TJjerapy, Amsterdam 1998: 65.
48. Cao Z, Harris N, Mendoza J, et al. Alkyl esters of 9 nitrocamptothecin: synthesis, toxicity and antitumor activity. Proc Am Ass Cancer Res 1998; 39: 420.